Sarah Bennett Starosta1, Stephen J Savage2. 1. Department of Urology, Medical University of South Carolina, 96 Jonathan Lucas St. CSB 644, Charleston, SC, 29425, USA. 2. Department of Urology, Medical University of South Carolina, 96 Jonathan Lucas St. CSB 644, Charleston, SC, 29425, USA. savages@musc.edu.
Abstract
PURPOSE OF REVIEW: To update treatment options and considerations for castration-resistant prostate cancer with specific attention to sequencing of agents based on available evidence and treatment rationale. RECENT FINDINGS: The newest research developments over the last several years include multicenter studies that address the sequencing of therapies to improve the treatment of metastatic castration-resistant prostate cancer. Chemotherapy agents, as well as androgen receptor antagonists, are evolving, and there are new tests available to define which patients are more likely to benefit. In addition, there have been some additional trials looking into the safety and efficacy of combination treatment and new therapies. There are multiple factors that should be considered to determine the sequence and/or combinations of therapies for metastatic castration-resistant prostate cancer that can improve quality of life and survival. Promising novel agents in combination with personalized medicine will likely continue to improve treatment of these patients.
PURPOSE OF REVIEW: To update treatment options and considerations for castration-resistant prostate cancer with specific attention to sequencing of agents based on available evidence and treatment rationale. RECENT FINDINGS: The newest research developments over the last several years include multicenter studies that address the sequencing of therapies to improve the treatment of metastatic castration-resistant prostate cancer. Chemotherapy agents, as well as androgen receptor antagonists, are evolving, and there are new tests available to define which patients are more likely to benefit. In addition, there have been some additional trials looking into the safety and efficacy of combination treatment and new therapies. There are multiple factors that should be considered to determine the sequence and/or combinations of therapies for metastatic castration-resistant prostate cancer that can improve quality of life and survival. Promising novel agents in combination with personalized medicine will likely continue to improve treatment of these patients.
Authors: Eric J Small; Paul F Schellhammer; Celestia S Higano; Charles H Redfern; John J Nemunaitis; Frank H Valone; Suleman S Verjee; Lori A Jones; Robert M Hershberg Journal: J Clin Oncol Date: 2006-07-01 Impact factor: 44.544
Authors: Joaquin Mateo; Suzanne Carreira; Shahneen Sandhu; Susana Miranda; Helen Mossop; Raquel Perez-Lopez; Daniel Nava Rodrigues; Dan Robinson; Aurelius Omlin; Nina Tunariu; Gunther Boysen; Nuria Porta; Penny Flohr; Alexa Gillman; Ines Figueiredo; Claire Paulding; George Seed; Suneil Jain; Christy Ralph; Andrew Protheroe; Syed Hussain; Robert Jones; Tony Elliott; Ursula McGovern; Diletta Bianchini; Jane Goodall; Zafeiris Zafeiriou; Chris T Williamson; Roberta Ferraldeschi; Ruth Riisnaes; Bernardette Ebbs; Gemma Fowler; Desamparados Roda; Wei Yuan; Yi-Mi Wu; Xuhong Cao; Rachel Brough; Helen Pemberton; Roger A'Hern; Amanda Swain; Lakshmi P Kunju; Rosalind Eeles; Gerhardt Attard; Christopher J Lord; Alan Ashworth; Mark A Rubin; Karen E Knudsen; Felix Y Feng; Arul M Chinnaiyan; Emma Hall; Johann S de Bono Journal: N Engl J Med Date: 2015-10-29 Impact factor: 91.245
Authors: Matthew R Smith; Fred Saad; Simon Chowdhury; Stéphane Oudard; Boris A Hadaschik; Julie N Graff; David Olmos; Paul N Mainwaring; Ji Youl Lee; Hiroji Uemura; Angela Lopez-Gitlitz; Géralyn C Trudel; Byron M Espina; Youyi Shu; Youn C Park; Wayne R Rackoff; Margaret K Yu; Eric J Small Journal: N Engl J Med Date: 2018-02-08 Impact factor: 91.245
Authors: Susan L Greenspan; Penelope Coates; Susan M Sereika; Joel B Nelson; Donald L Trump; Neil M Resnick Journal: J Clin Endocrinol Metab Date: 2005-09-27 Impact factor: 5.958
Authors: Tomasz M Beer; Eugene D Kwon; Charles G Drake; Karim Fizazi; Christopher Logothetis; Gwenaelle Gravis; Vinod Ganju; Jonathan Polikoff; Fred Saad; Piotr Humanski; Josep M Piulats; Pablo Gonzalez Mella; Siobhan S Ng; Dirk Jaeger; Francis X Parnis; Fabio A Franke; Javier Puente; Roman Carvajal; Lisa Sengeløv; M Brent McHenry; Arvind Varma; Alfonsus J van den Eertwegh; Winald Gerritsen Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Laura B Oswald; Frank A Schumacher; Brian D Gonzalez; Kelvin A Moses; David F Penson; Alicia K Morgans Journal: Patient Prefer Adherence Date: 2020-10-14 Impact factor: 2.711